Facit

What is Facit?

FACIT is a venture capital firm based in Toronto, Ontario, with a sole focus on developing the province's cancer research industry. They target investments in healthcare, oncology, life science, and health tech sectors, with an emphasis on commercializing cancer breakthroughs and fostering economic growth. FACIT operates with the mandate to seed and scale Ontario's premier entrepreneurial ventures not only for patient benefit but also to enhance the local economy.

Their operation strategy encompasses leveraging breakthrough innovations and a robust community network, investing seed capital in startups, and securing strategic partnerships. To maximize the potential of local biotech ventures, FACIT also works on driving clinical trials, job creation, and talent development.

Their approach is to create a sustainable biotech environment in Ontario and they strive to increase the value of Ontario's oncology innovations, thus attracting further private sector investment. This results in a multiplication of the impact as additional financing is attracted, and new Ontario startups are fostered, which then transition into conducting first-in-human studies.

FACIT is notable for bridging the life sciences seed funding gap in Ontario. Their investment portfolio positions them at the forefront of Ontario's biotech ecosystem, with significant partnerships and clinical trials fostering job creation and leveraged financing for the province.

FACIT's key successes are celebrated at events such as the Falcon's Fortunes pitch competition, which bolsters the province's entrepreneurial spirit within the cancer research community. FACIT is established by the Ontario Institute for Cancer Research (OICR) to fill critical roles in commercialization, technology transfer, and development activities, aligning closely with OICR to drive R&D investment in Ontario and bring promising oncology innovations to market.

What they say:

We are designed to support academic institutions in Ontario.

What we look for: We invest in early-stage proof-of-concept studies.